Geron Corporation (GERN) Announces Initiation of Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer

Geron Corporation (Nasdaq: GERN) today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases – Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer. GRN1005 is the company's lead LRP-directed peptide-drug conjugate (LRP-directed PDC) that consists of the cytotoxic drug, paclitaxel, linked to a peptide (Angiopep-2) that targets the LRP receptor to cross the blood-brain barrier (BBB) and to target tumors in the brain.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
• Dr. Reddy’s Labs (RDY) Launches Generic OTC Prevacid (NVS)
• Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Esbriet (pirfenidone) Positive GBA Assessment

Create E-mail Alert Related Categories

FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter